EX-10.32



 [*] = Certain confidential information contained in this document, marked by brackets, is filed with the
Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 Exhibit 10.32 

 

			
	 UNIVERSITY OF CALIFORNIA, BERKELEY
  

OFFICE OF TECHNOLOGY LICENSING
		



            

  
  

 
 AMENDMENT # 1 

TO: 
 THE EXCLUSIVE
LICENSE AGREEMENT BETWEEN ADURO BIOTECH INC. AND 
 THE REGENTS 

FOR 

CYCLIC-DI-NUCLEOTIDES THAT STIMULATE HUMAN STING VARIANTS 

ANDSTIMULATOR OF INTERFERON GENE 

UC Case No.: [*] 
 Agreement
Control No. 2015-04-0045 
  
  

 
 This first amendment (“AMENDMENT # 1”) to
the exclusive license agreement (the “AGREEMENT”) between the REGENTS OF THE UNIVERSITY OF CALIFORNIA, a California corporation, whose legal address is 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200, acting through
its Office of Technology Licensing, at the University of California, Berkeley, 2150 Shattuck Avenue, Suite 510, Berkeley, CA 94704-1347 (“REGENTS”) and ADURO BIOTECH, INC, a Delaware corporation having a principal place of business
at 626 Bancroft Way, 3C, Berkeley, CA 94710 (“LICENSEE”) is effective as of March 4, 2015. 
 The parties agree to amend the referenced license
agreement as follows: 
 Article 2 (DEFINITIONS), substitute paragraph 2.5 in its entirety with the following: 

 

	 	2.5	 “Joint PATENT RIGHTS” means (i) U.S. Patent Application Serial Number [*] and assigned to REGENTS and LICENSEE; (ii) U.S. Patent Application
Serial Number [*] and assigned to REGENTS and LICENSEE; (iii) U.S. Patent Application Serial Number [*] and assigned to REGENTS and LICENSEE; (iv) PCT Application Serial Number [*] and assigned to REGENTS and LICENSEE; (v) any patent applications,
utility models, inventors certificates, invention registrations, continuing applications, divisional applications, substitutions, continuation-in-



  

					
	 Aduro Biotech Inc.
 CONFIDENTIAL
		Page 1 of 2		
Amend. # 1 (REVC) to EXCL 
2015-04-0045
 UC Case No.: B13-136 & B14-143











	 	
part applications, and equivalents thereof in any jurisdiction anywhere in the world, in each case to the extent that claims in such filings are entitled to the filing date of the patent
applications in (i)-(iv); and (vi) any granted patents issuing on (i)-(v) including any reissues, re-examinations, or extensions thereof. 


All remaining terms and conditions of the AGREEMENT between Licensee and Regents, which bears an effective date of September 25, 2014, remain in full force
and effect. 
 IN WITNESS WHEREOF, the parties hereto have executed this Amendment # 1 in duplicate originals by their duly authorized officers and
representatives. The parties to this document agree that a copy of the original signature to this Agreement (including an electronic copy) may be used for any and all purposes for which the original signature may have been used. The parties further
waive any right to challenge the admissibility or authenticity of this document in a court of law based solely on the absence of an original signature. 
  

									
	THE REGENTS OF THE				ADURO BIOTECH, INC.
	UNIVERSITY OF CALIFORNIA						
					
	By		         /s/ Irvin J. Mettler
				By		         /s/ Thomas Dubensky

					
			         Irvin J. Mettler, Ph.D.

        Associate Director

        Office of Technology Licensing
				Name		              Thomas
Dubensky

					  
 Title
		              Chief Scientific
Officer

					
	Date		   March 6, 2015
				Date		   03.05.2015



  

					
	 Aduro Biotech Inc.
 CONFIDENTIAL
		Page 2 of 2		
Amend. # 1 (REVC) to EXCL 
2015-04-0045
 UC Case No.: B13-136 & B14-143



[*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to
Rule 406 of the Securities Act of 1933, as amended.